Literature DB >> 26124364

Epidermal Growth Factor Receptor Expression May Correlate with Survival Through Clinical and Radiological Features of Aggressiveness in Glioblastoma Treated with Radiochemotherapy.

Paolo Tini1, Alfonso Cerase2, Gabriele Cevenini3, Salvatore F Carbone4, Clelia Miracco5, Luigi Pirtoli6.   

Abstract

AIM: To analyze the correlation between epidermal growth factor receptor (EGFR) expression and clinicoradiological features in patients with glioblastoma. PATIENTS AND METHODS: Select clinical (age, Karnofsky performance status, neurological performance status) and neuroradiological (multiple tumor incidence, peritumoral edema, response to treatment) prognostic variables were correlated with EGFR expression levels estimated on pathological samples in 144 patients who had undergone postoperative radiochemotherapy treatment.
RESULTS: Clinical and radiological prognostic parameters, including synchronous multiple tumor, extent of edema, and radiological response after therapy, showed a statistically significant correlation with the EGFR expression score. Patients with a high EGFR expression seemed to present worse cliniconeurological status and radiological features of tumor aggressiveness (higher incidence of multiple tumor, major extent of peritumoral edema and poorer radiological response to treatment).
CONCLUSION: A potential correlation between high EGFR expression and aggressive clinical and radiological features of GB seems to exist, leading to worse prognosis in these patients. Copyright
© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  EGFR; Glioblastoma; peritumoral edema; radiotherapy; response assessment

Mesh:

Substances:

Year:  2015        PMID: 26124364

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  A Survival Score Based on Symptoms and Performance Status for Patients with High-grade Gliomas Receiving Radiochemotherapy.

Authors:  Pham Cam Phuong; LE Viet Nam; Steven E Schild; Dirk Rades; Mai Trong Khoa
Journal:  In Vivo       Date:  2017 Jul-Aug       Impact factor: 2.155

2.  Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide.

Authors:  Alexandra McAleenan; Claire Kelly; Francesca Spiga; Ashleigh Kernohan; Hung-Yuan Cheng; Sarah Dawson; Lena Schmidt; Tomos Robinson; Sebastian Brandner; Claire L Faulkner; Christopher Wragg; Sarah Jefferies; Amy Howell; Luke Vale; Julian P T Higgins; Kathreena M Kurian
Journal:  Cochrane Database Syst Rev       Date:  2021-03-12

3.  BRAF mutations may identify a clinically distinct subset of glioblastoma.

Authors:  Samantha N McNulty; Katherine E Schwetye; Cole Ferguson; Chad E Storer; George Ansstas; Albert H Kim; David H Gutmann; Joshua B Rubin; Richard D Head; Sonika Dahiya
Journal:  Sci Rep       Date:  2021-10-08       Impact factor: 4.379

Review 4.  Molecular Biomarkers in Glioblastoma: A Systematic Review and Meta-Analysis.

Authors:  Heena Sareen; Yafeng Ma; Therese M Becker; Tara L Roberts; Paul de Souza; Branka Powter
Journal:  Int J Mol Sci       Date:  2022-08-09       Impact factor: 6.208

5.  Prognostic significance of epidermal growth factor receptor expression in glioma patients.

Authors:  Junhong Li; Ruofei Liang; Chen Song; Yufan Xiang; Yanhui Liu
Journal:  Onco Targets Ther       Date:  2018-02-07       Impact factor: 4.147

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.